GeoVax Advocates for MVA-Based Vaccines Following HHS mRNA Vaccine Rollback

The U.S. Department of Health and Human Services (HHS) has recently terminated nearly $500 million in BARDA-funded mRNA vaccine development contracts, signaling a significant policy shift. This decision was influenced by concerns regarding the effectiveness of mRNA vaccines against viruses that infect the upper respiratory tract, as highlighted by HHS Secretary Kennedy. GeoVax Labs, Inc. has responded to this development by advocating for its MVA-based multi-antigen vaccines, such as GEO-CM04S1 for COVID-19, which are designed to offer broader and more durable protection against viruses, including those that mutate.

GeoVax's GEO-CM04S1 vaccine candidate expresses both the Spike (S) and Nucleocapsid (N) proteins of SARS-CoV-2, a feature that enables it to induce robust and durable immune responses across various virus variants. Clinical studies have demonstrated the vaccine's effectiveness, even among immunocompromised patients, setting it apart from mRNA vaccines that target a single antigen and may encourage viral mutations. David Dodd, Chairman and CEO of GeoVax, emphasized that the MVA-based platform addresses the limitations of mRNA vaccines, offering a promising solution to the challenges outlined by Secretary Kennedy.

The advantages of GeoVax's MVA-based vaccines extend beyond their multi-antigen design. These vaccines are safe for vulnerable populations, including immunocompromised individuals, pregnant women, and children, and are manufactured using innovative processes that support scalable, decentralized U.S. vaccine production. This approach not only ensures faster production and higher yields at reduced costs but also aligns with national priorities for pandemic preparedness and biodefense. GeoVax's pipeline includes vaccines targeting a range of infectious diseases, further underscoring the platform's versatility and potential to enhance public health resilience.

In light of these developments, GeoVax is urging HHS to support multi-antigen vaccine platforms like MVA as part of a diversified biomedical countermeasure strategy. The company is ready to collaborate with federal partners under programs such as the FDA’s Commissioner’s National Priority Voucher (CNPV) to accelerate regulatory and funding support for its vaccine candidates. GeoVax's commitment to advancing vaccine technology reflects a broader vision for national immunization security, leveraging lessons learned from the COVID-19 pandemic to prepare for future public health challenges.